- Home
- IDYA vs NVCR Comparison
IDYA vs NVCR Comparison
Compare IDYA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- NVCR
- Stock Information
- Founded
- IDYA 2015
- NVCR 2000
- Country
- IDYA United States
- NVCR Switzerland
- Employees
- IDYA N/A
- NVCR 1488
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- NVCR Medical/Dental Instruments
- Sector
- IDYA Health Care
- NVCR Health Care
- Exchange
- IDYA Nasdaq
- NVCR Nasdaq
- Market Cap
- IDYA 2.0B
- NVCR 2.0B
- IPO Year
- IDYA 2019
- NVCR 2015
- Fundamental
- Price
- IDYA $21.67
- NVCR $16.69
- Analyst Decision
- IDYA Strong Buy
- NVCR Buy
- Analyst Count
- IDYA 12
- NVCR 6
- Target Price
- IDYA $54.27
- NVCR $32.83
- AVG Volume (30 Days)
- IDYA 1.2M
- NVCR 1.6M
- Earning Date
- IDYA 08-05-2025
- NVCR 07-24-2025
- Dividend Yield
- IDYA N/A
- NVCR N/A
- EPS Growth
- IDYA N/A
- NVCR N/A
- EPS
- IDYA N/A
- NVCR N/A
- Revenue
- IDYA $7,000,000.00
- NVCR $621,711,000.00
- Revenue This Year
- IDYA $101.20
- NVCR $5.56
- Revenue Next Year
- IDYA $286.70
- NVCR $9.19
- P/E Ratio
- IDYA N/A
- NVCR N/A
- Revenue Growth
- IDYA N/A
- NVCR 18.27
- 52 Week Low
- IDYA $13.45
- NVCR $14.17
- 52 Week High
- IDYA $44.42
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- IDYA 58.21
- NVCR 43.44
- Support Level
- IDYA $21.09
- NVCR $17.20
- Resistance Level
- IDYA $22.50
- NVCR $18.02
- Average True Range (ATR)
- IDYA 0.97
- NVCR 1.04
- MACD
- IDYA -0.04
- NVCR -0.09
- Stochastic Oscillator
- IDYA 56.44
- NVCR 15.51
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.